These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32716573)

  • 1. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
    Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
    Roth KG; Mambetsariev I; Salgia R
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
    Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
    Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
    Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape.
    Simard MA; Cabrera-Galvez C; Viteri S; Geist F; Reischmann N; Zühlsdorf M; Karachaliou N
    Neoplasia; 2024 Nov; 57():101063. PubMed ID: 39366215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
    Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
    Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
    Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
    Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
    Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML; Passiglia F; Cappuzzo F; Minuti G; Occhipinti M; Bulotta A; Delmonte A; Sini C; Galetta D; Roca E; Pelizzari G; Cortinovis D; Gariazzo E; Pilotto S; Citarella F; Bria E; Muscolino P; Pozzessere D; Carta A; Pignataro D; Calvetti L; Leone F; Banini M; Di Micco C; Baldini E; Favaretto A; Malapelle U; Novello S; Pasello G; Tiseo M
    ESMO Open; 2024 Sep; 9(9):103680. PubMed ID: 39214048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
    Xiong W; Hietala SF; Nyberg J; Papasouliotis O; Johne A; Berghoff K; Goteti K; Dong J; Girard P; Venkatakrishnan K; Strotmann R
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):53-69. PubMed ID: 35771259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.